Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

* Subject has given written informed consent before any trial-related activities are carried out
* Male or female, greater than or equal to (\>=)18 years of age at the time of informed consent, inpatient or outpatient
* Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIB NSCLC with pleural effusion or stage IV
* Presence of at least 1 uni-dimensionally measurable index lesion, whereby index lesions must not lie in a previously irradiated area
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at inclusion in the trial
* White blood count\>= 3 \* 10\^9 per liter (/L) with neutrophils \>= 1.5 \* 10\^9 /L , platelet count \>=100 \* 10\^9 /L , and hemoglobin \>= 5.6 millimole per liter (mmol/L) (9 gram per deciliter \[g/dL\])
* Total bilirubin less than or equal to (=\<)1.5 \* upper limit of normal (ULN) range
* Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) =\< 5 \* ULN
* Glomerular filtration rate (GFR) \>=60 milliliter per minute (mL/min). The creatinine clearance (CrCl) estimated based on the Cockroft-Gault formula is used as a surrogate for the GFR
* Effective contraception that is, barrier method (condoms, diaphragm), oral, injectable or implant birth control, for both male and female subjects during the whole trial period and for at least 6 months after the end of trial treatment, if the risk of conception exists
* Recovered from relevant toxicities prior to inclusion in the trial

Exclusion Criteria:

* Previous exposure to Epidermal Growth Factor Receptor (EGFR)-targeting therapy
* Previous chemotherapy for NSCLC; neo-adjuvant or adjuvant (radio-)chemotherapy is allowed if it was finished 6 months prior to start of trial treatment
* Major surgery within 30 days prior to inclusion in the trial
* Prior chest irradiation within 90 days prior to inclusion in the trial (palliative radiation of bone lesions is allowed)
* Participation in another clinical trial or treatment with any investigational agent(s) within 30 days prior to inclusion in the trial
* Concurrent chronic systemic immune therapy, chemotherapy for disease other than cancer, or hormone therapy for the treatment of cancer not indicated in the trial protocol
* Documented or symptomatic brain metastasis
* Pre-existing ascites Grade \>= 2 and/or pericardial effusion Grade \>= 2
* Superior vena cava syndrome contra-indicating hydration
* Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
* Active infection (infection requiring intravenous antibiotics), including active tuberculosis, known and declared human immunodeficiency virus (HIV)
* Myocardial infarction within 6 months prior to inclusion into the trial, uncontrolled congestive heart failure; or any current Grade 3 or 4 cardio-vascular disorder despite treatment
* Known hypersensitivity reaction to any of the components of trial treatments
* Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade \>= 2 and/or ototoxicity Grade \>= 2, except if due to trauma or mechanical impairment due to tumor mass
* History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder
* Medical or psychological condition that would not permit the subject to complete the trial or sign informed consent
* Legal incapacity or limited legal capacity
* Known drug abuse
* Pregnancy (absence to be confirmed by serum beta-human chorionic gonadotropin \[beta-HCG test\]) or lactation period